Clinical Trials Logo

Hearing Loss clinical trials

View clinical trials related to Hearing Loss.

Filter by:

NCT ID: NCT03662256 Completed - Hearing Loss Clinical Trials

Reducing Childhood Hearing Loss in Rural Alaska Through a Preschool Screening and Referral Process Using Mobile Health and Telemedicine

Start date: September 7, 2018
Phase: N/A
Study type: Interventional

The population in rural Alaska, which is predominately Alaska Native, experiences a disproportionately high burden of hearing loss compared to the general US population. The impact of untreated hearing loss in early childhood is tremendous and has grave implications for school achievement. Preschool children with hearing loss experience speech and language delays and are less likely to be ready for kindergarten than their normal-hearing peers. Early identification and treatment can reverse these ill effects. Importantly, the majority of hearing loss in this age group in rural Alaska is infection-mediated, arising from acute and chronic otitis media that is treatable. In response, preschool hearing screening is federally mandated at all Head Start centers across the country. In accordance with this mandate, hearing screening is already performed by the three organizations that offer early childhood education in the Norton Sound region: Kawerak Inc, RurAL CAP, and Bering Strait School District. While the concept of screening in this age group is well established nationally, what is less well understood is the optimal screening protocol for preschool children. There is little evidence evaluating sensitivity and specificity of different screening protocols in this age group. Further, loss to follow up in the referral stage is a problem in preschool hearing screening just as it is in school hearing screening. Alaska has already developed innovative strategies to address hearing loss. A network of village health clinics staffed by community health aides provide local care, and telemedicine has been adopted in over 250 village clinics statewide. Despite being widely available, telemedicine has not yet been used to speed up the referral process for preventive services such as hearing screening. Norton Sound Health Corporation has partnered with Duke and Johns Hopkins Universities to evaluate hearing screening and referral processes in early childhood education in the Norton Sound region of northwest Alaska. Preschool children will receive screening from the preschool and a new mHealth screening protocol. These will be compared against a benchmark audiometric assessment to determine sensitivity and specificity. Communities will then be randomized to continue the current primary care referral process or to adopt telemedicine referral. The primary outcome will be time to ICD-10 ear/hearing diagnosis. Secondary outcomes will include sensitivity and specificity of screening protocols and prevalence of hearing loss. The goal of this study is to evaluate the optimal screening and referral strategy for preschool children in rural Alaska.

NCT ID: NCT03652909 Completed - Hearing Loss Clinical Trials

Personal Sound Amplification Smartphone Application Feasibility

PSAD
Start date: February 26, 2021
Phase:
Study type: Observational

Find a personal sound amplification device that can help people hear better.

NCT ID: NCT03616223 Completed - Clinical trials for Sensorineural Hearing Loss

FX-322 in Sensorineural Hearing Loss

Start date: July 3, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

This is a phase 1/2 study of FX-322 at two dose levels compared to placebo in male and female adults otherwise healthy with stable sensorineural hearing loss.

NCT ID: NCT03613909 Completed - Clinical trials for Hearing Loss, Sensorineural

Acceptance of the CP950 Sound Processor

Start date: November 2015
Phase: N/A
Study type: Interventional

Acceptance of CP950 sound processor with experienced CP810/CP910/CP920 BTE sound processor users.

NCT ID: NCT03603314 Completed - Clinical trials for Severe Sudden Sensorineural Hearing Loss

Efficacy of SENS 401 in Subjects With Severe or Profound Sudden Sensorineural Hearing Loss

AUDIBLE-S
Start date: February 15, 2019
Phase: Phase 2/Phase 3
Study type: Interventional

Primary objective of the study is to assess the efficacy of SENS-401 on hearing loss in comparison to placebo at the end of the 4-week treatment period

NCT ID: NCT03594500 Completed - Hearing Loss Clinical Trials

Hearing Impairment, Strategies, and Outcomes in Emergency Departments

Hear-VA
Start date: March 18, 2019
Phase: N/A
Study type: Interventional

Aim 1: Establish the feasibility of screening for hearing loss in the ED Aim 2: Determine the acceptability of the screening procedure (among the ED population) Aim 3: Derive a preliminary estimate of the effect size of primary outcomes Aim 4: Identify the evidence that decision makers in Veteran Affair Medical Centers, ED and Audiology Services need to commit to this approach

NCT ID: NCT03587792 Completed - Clinical trials for Unilateral Hearing Loss

Study of Binaural Squelch Effect in Unilateral Otosclerosis

CBOU
Start date: March 6, 2018
Phase:
Study type: Observational [Patient Registry]

Patients with unilateral transmission hypoacusis due to otosclerosis undergoing stapedectomy surgery will be prospectively included. They will be undergoing a free field vocal audiometry using the Oldenburg MATRIX software to evaluated the squelch effect gain between audiometry before and after 9months after surgery. Our hypothesis is to show a squelch effect with the rehabilitation of the binaural audition.

NCT ID: NCT03582566 Completed - Clinical trials for Hearing Loss, Sensorineural

Training Language and Literacy for Children Who Use CIs

Start date: July 1, 2016
Phase: N/A
Study type: Interventional

This study aims to determine the effectiveness of computer games to improve language and literacy outcomes for children who have hearing loss. Children will be assigned to one of four conditions: phonological awareness training, working memory training, phonological awareness + working memory training, or active control.

NCT ID: NCT03578471 Completed - Hearing Loss Clinical Trials

Assessment of Novel Sound Changing Principles in Hearing Instruments to Determine Their Application - 2018_16

Start date: June 4, 2018
Phase: N/A
Study type: Interventional

An EEG study using continuous speech stimuli to assess neural language processing in a hearing impaired population. Participants listen to short radio excerpts in different Signal to Noise Ratios (SNR) and answer comprehension questions as well as listening effort questions. We assess the effect of different algorithms on neural language processing as well as subjective listening effort. Each participant hears 12 randomized segments of speech (about 4min long each) with different settings on their hearing aid (reference condition, noise reduction algorithm, beam forming algorithm). This will be a controlled, single blinded and randomized active comparator clinical evaluation which will be conducted mono centric at Sonova AG Headquarter based in Stäfa.

NCT ID: NCT03575390 Completed - Hearing Impairment Clinical Trials

The Beneficial Effects of Pomegranate on Hearing of Patients Without Hemodialysis

Start date: March 30, 2018
Phase: N/A
Study type: Interventional

Pomegranate has anti-oxidative capacity. It might reduce symptoms of Alzheimer's disease, Drug-induced hepatitis, and might prevent deterioration of cardiovascular diseases and cancer progression. But, the beneficial effects of pomegranate on hearing impairment was still unclear. This study aimed to investigate the beneficial effects of pomegranate on hearing impairment by a prospective, randomized, double-blinded clinical trial design. The investigators'll include 120 elderly patients without hemodialysis in our hospital, and divided them into 2 groups. Control group will receive placebo treatment; pomegranate group will receive oral pomegranate (500 mg, twice per day). All patients received the above treatment for 9 months, and underwent pure tone audiometry and word discrimination scores before the start of the clinical trial and at the end of the treatment (9th month).